3-MeO-PCE (3-Methoxyeticyclidine): Complete Toxicology, Deaths, Metabolism & Safety Monograph

3-MeO-PCE (3-Methoxyeticyclidine): Complete Toxicology, Deaths, Metabolism & Safety Monograph

Emergency dissociative toxicity: Severe unresponsiveness, seizure, abnormal breathing, dangerous agitation/confusion, chest pain, persistent vomiting with reduced consciousness, collapse, or behavior that creates immediate risk of serious injury requires urgent medical care.

Quick answer

3-MeO-PCE is 3-methoxyeticyclidine, a PCP/PCE-type arylcyclohexylamine dissociative that acts primarily through NMDA-receptor antagonism.

Compared with many current research-chemical dissociatives, its evidence base is no longer purely theoretical.

It now includes:

• severe human intoxication reports;
• a fatal multidrug case;
• authentic human urine metabolism;
• forensic blood data;
• a 2026 death from traumatic self-defenestration in which acute dissociation/agitation may have contributed.

The evidence still does not establish a safe dose, human half-life, dependence incidence, or universal toxic concentration.

Identity

History

3-MeO-PCE belongs to a lineage that begins with PCP and PCE/eticyclidine medicinal chemistry.

PCP was developed as an anesthetic but became unsuitable for routine human use because of severe psychological emergence effects.

PCE and related compounds were explored as dissociative anesthetic analogues.

3-MeO-PCE later reappeared in research-chemical markets and was reported to the European early-warning system in 2010.

It is therefore one of the older modern arylcyclohexylamine NPS, even though detailed human toxicology remained sparse for years.

Pharmacology

3-MeO-PCE is generally classified as a PCP-type NMDA receptor antagonist.

The 2024 metabolism paper describes it as having higher NMDA-receptor binding affinity than PCP based on prior literature.

NMDA antagonism can produce:

• dissociation;
• altered perception;
• analgesia;
• amnesia;
• impaired coordination;
• psychotomimetic effects;
• behavioral disorganization.

Beyond NMDA

Some experimental arylcyclohexylamine research suggests PCP/PCE analogues can interact with monoamine transporters and other targets.

However, the clinical significance of those secondary targets for 3-MeO-PCE is not sufficiently defined to create a consumer interaction or potency chart.

Severe human intoxication

Clinical literature includes a severe intoxication report involving a young adult who mistakenly used 3-MeO-PCE instead of another NPS.

The case involved:

• altered/reduced consciousness;
• vomiting;
• need for emergency medical evaluation.

The literature remains too small to define a typical isolated 3-MeO-PCE toxidrome.

2021 fatal multidrug case

A 42-year-old man was found dead with multiple research-chemical powders.

Analytical testing confirmed:

• 2F-DCK;
• 3-MeO-PCE;
• 5-MeO-DMT;
• evidence of amphetamine, cocaine and cannabis use.

Peripheral blood contained measurable 3-MeO-PCE.

Investigators attributed the death to respiratory depression from a drug cocktail, with 2F-DCK considered the main contributor.

Therefore:

This case establishes 3-MeO-PCE involvement in a fatal polysubstance intoxication, not a 3-MeO-PCE-only lethal concentration.

September 2026 self-defenestration case

A newly published 2026 forensic report described a 33-year-old man who died after falling approximately 5.8 meters from an apartment window.

Peripheral blood contained:

• 3-MeO-PCE;
• 3-HO-PCE, a metabolite;
• tramadol;
• ethanol.

Traumatic injuries were the immediate cause of death.

The authors concluded that 3-MeO-PCE-related dissociation or agitation—potentially amplified by tramadol/alcohol—may have contributed to the circumstances of the fall.

Why this matters

Dissociative harm is not limited to direct organ toxicity.

Severe impairment can create fatal risk through:

• falls;
• traffic;
• drowning;
• wandering into unsafe environments;
• impulsive or disorganized behavior.

Acute toxicity

Potential severe effects include:

• profound dissociation;
• confusion;
• agitation;
• psychotic-like behavior;
• impaired consciousness;
• vomiting/aspiration risk;
• hypertension/tachycardia;
• inability to coordinate movement;
• injury.

Rare/severe complications in mixed exposures can include respiratory compromise or death.

Behavioral and psychiatric toxicity

PCP-like dissociatives can produce:

• paranoia;
• disorganized thinking;
• agitation;
• hallucinations;
• impaired reality testing.

The 2026 trauma case adds concrete forensic evidence that behavioral disturbance can contribute materially to harm even when the drug is not the anatomical cause of death.

Respiratory risk

3-MeO-PCE is not an opioid and does not have the same primary respiratory mechanism as fentanyl.

However:

• profound unconsciousness can compromise airway protection;
• vomiting creates aspiration risk;
• alcohol/opioids/other depressants can add respiratory depression;
• the 2021 fatal case involved a multidrug respiratory-depression scenario.

Interactions

No controlled interaction studies define safe combinations.

Important concerns include:

• alcohol/benzodiazepines → deeper unconsciousness and aspiration risk;
• opioids → opioid-driven respiratory depression;
• tramadol → seizure/serotonergic/respiratory complexity;
• stimulants → cardiovascular stress and behavioral agitation;
• other dissociatives → unpredictable depth and duration.

Metabolism

A 2024 study used:

• human liver microsomes;
• zebrafish model;
• two authentic human urine samples.

Researchers identified 14 metabolites across experimental systems.

Proposed pathways included:

• hydroxylation;
• O-demethylation;
• N-dealkylation;
• dehydrogenation;
• combined transformations;
• glucuronidation;
• sulfation.

3-HO-PCE and other biomarkers

The authentic urine study detected parent 3-MeO-PCE plus three metabolites.

The authors recommended a hydroxylation product as a useful biomarker for documenting intake.

The 2026 self-defenestration case also detected 3-HO-PCE in blood, strengthening the practical forensic relevance of metabolite-aware testing.

Pharmacokinetics

There is no robust controlled human PK study establishing:

• bioavailability;
• time to peak;
• terminal half-life;
• clearance;
• accumulation;
• concentration-response.

A postmortem concentration or urine metabolite pattern is not a substitute for human PK.

Drug testing

Routine immunoassays

Routine drug panels should not be assumed to identify 3-MeO-PCE.

A PCP screen may have uncertain cross-reactivity and cannot replace compound-specific confirmation.

Definitive testing

Published cases used methods such as:

• LC-MS/MS;
• LC-HRMS;
• NMR for drug-material identification;
• metabolite-aware urine analysis.

Novel dissociatives require continuously updated analytical libraries.

Product identity

Research-chemical powders can be mislabeled or substituted.

A clinical report involving accidental use of 3-MeO-PCE instead of another NPS illustrates why seller/product name is not analytical identity.

Different PCP/PCE/ketamine analogues can have substantially different potency and duration.

Tolerance

Repeated NMDA-antagonist exposure can produce tolerance.

No controlled 3-MeO-PCE study establishes:

• speed of tolerance;
• cross-tolerance with PCP, ketamine, O-PCE or DCK;
• whether tolerance develops equally to behavioral impairment and organ risk.

Tolerance should not be treated as a license to escalate exposure.

Dependence and problematic use

The 2021 fatal case included hair evidence consistent with months of repeated experimentation with multiple NPS.

That supports a real-world pattern of repeated use but does not quantify 3-MeO-PCE-specific dependence.

PCP-like dissociatives can support compulsive use in some people.

The exact incidence for 3-MeO-PCE remains unknown.

Withdrawal

No validated 3-MeO-PCE withdrawal syndrome or timeline exists.

After frequent dissociative use, possible problems can include:

• craving;
• low mood;
• irritability;
• sleep disturbance;
• anxiety;
• difficulty stopping.

These are class/repeated-use concerns, not a proven drug-specific withdrawal curve.

Treatment and support

There is no medication approved specifically for 3-MeO-PCE use disorder.

Acute intoxication is managed supportively based on:

• consciousness;
• airway;
• cardiovascular state;
• agitation;
• injuries;
• co-drugs.

Problematic use can be treated through substance-use and mental-health care.

U.S. resources include FindTreatment.gov and SAMHSA 1-800-662-HELP (4357).

Forensic interpretation

Concentration is not dose

The fatal 2021 and 2026 cases provide useful reference concentrations.

They do not establish:

• safe levels;
• lethal thresholds;
• impairment cutoffs.

Trauma can be drug-associated without being drug-caused anatomically

In the 2026 case, trauma killed the person.

The drug may still have contributed behaviorally.

That distinction is important in forensic causation.

Metabolites improve confidence

Finding parent 3-MeO-PCE plus an expected metabolite such as 3-HO-PCE strengthens evidence of true exposure.

Special populations

Controlled data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• seizure disorders;
• psychotic/bipolar disorders;
• liver/kidney disease.

People vulnerable to psychosis/mania may face particular concern from PCP-like psychotomimetic effects, though exact risk is unknown.

Legal status — dated October 2, 2026

International

UNODC states that 3-MeO-PCE is not under international control.

United States

This review does not identify a current federal scheduling action specifically naming 3-MeO-PCE in the primary sources used here.

Related PCP/PCE compounds are controlled, and analogue-law/state-law treatment can differ.

Exact legal status should be checked by molecule, jurisdiction and date.

Myths and misconceptions

“3-MeO-PCE is just ketamine with a different duration.”
False. It belongs to a PCP/PCE-type chemical lineage and has a different evidence base.

“The 2021 death proves 3-MeO-PCE has a fatal blood level around the measured concentration.”
False. It was a complex multidrug fatality.

“The 2026 death proves 3-MeO-PCE directly killed the person.”
No. Trauma was the immediate cause; drug-related behavioral impairment may have contributed.

“A PCP screen reliably detects it.”
Not necessarily.

“No international scheduling means it is safe.”
False. Legal control and toxicology are different questions.

Evidence ledger

Related evidence

• 3-HO-PCP
• O-PCE
• DCK
• 2F-DCK
• FXE
• RC dissociatives evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

3-MeO-PCE now has enough human evidence to move beyond a generic “research chemical dissociative” label.

The strongest modern evidence shows serious intoxication, complex fatal polysubstance exposure, measurable human metabolites, and a credible pathway from dissociation/agitation to fatal accidental trauma.

What science still cannot responsibly give is a safe dose, clean human potency ratio, universal half-life or fatal concentration.